Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent <i>in vivo</i> antitumor activitySauveur-Michel Maira, Carlos García-Echeverría, Alain De Pover et al.|Molecular Cancer Therapeutics|2008Cited by 1.1k
Specific apoptosis induction by the dual PI3K/mTor inhibitor NVP-BEZ235 in HER2 amplified and PIK3CA mutant breast cancer cellsSaskia M. Brachmann, Sauveur-Michel Maira|Proceedings of the National Academy of Sciences|2009Cited by 319
Discovery, Preclinical Characterization, and Early Clinical Activity of JDQ443, a Structurally Novel, Potent, and Selective Covalent Oral Inhibitor of KRASG12CAndreas Weiss, Saskia M. Brachmann, Edwige Lorthiois et al.|Cancer Discovery|2022Cited by 134
CRISPR Screening Identifies Mechanisms of Resistance to KRASG12C and SHP2 Inhibitor Combinations in Non–Small Cell Lung CancerAnirudh Prahallad, Saskia M. Brachmann|Cancer Research|2023Cited by 27